Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04201782 · ClinicalTrials.gov registry record
Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T
A clinical trial, sponsored by Sangamo Therapeutics.
- Terminated
- Registry status
- 38
- Enrollment target
NCT04201782: Clinical Trial study, sponsored by Sangamo Therapeutics.
NCT04201782 is a clinical trial that was terminated before completion, run by Sangamo Therapeutics. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04201782 was terminated before completion, sponsored by Sangamo Therapeutics.
- TERMINATED
- Registry status
- 38 participants
- Enrollment target
Study Summary
Long-term follow-up of HIV-infected subjects who received SB-728-T or SB-728mR-T. Enrolling subjects will be followed for a total of 12 years.
Primary Outcome
Number of subjects with SAEs. Number of subjects with delayed adverse events associated with administration of SB-728-T or SB-728mR-T, autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases. Incidence of new malignancies, neurologic disorders (new or exacerbation of pre-existing), rheumatologic disease (new or exacerbation of pre-existing), autoimmune disorder (new or pre-existing), and new hematologic disorder.
Interventions
- DRUG There are no disallowed treatments
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-03-18 |
| Est. Completion | 2023-07-17 |
Why NCT04201782 stopped before completion
NCT04201782 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which There are no disallowed treatments is the first listed.
NCT04201782 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04201782 about?
NCT04201782 is a clinical study titled "Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T". Long-term follow-up of HIV-infected subjects who received SB-728-T or SB-728mR-T. Enrolling subjects will be followed for a total of 12 years.
What is the current status of trial NCT04201782?
This trial is currently terminated. The enrollment target is 38 participants. The study started on 2011-03-18. Estimated completion is 2023-07-17.
What interventions are being tested in trial NCT04201782?
The interventions under investigation include: There are no disallowed treatments (DRUG).
Who is sponsoring clinical trial NCT04201782?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI